Beecher Reagan Welcomes Jeff Harms as Managing Director
Jeff's extensive client experience spans professional services, private equity and industry-leading corporate entities. He has decades of experience conducting CIO, CTO, CDO, CISO, CPO and Consulting Leadership searches in multiple industry sectors, working cross-functionally in digital and technology segments that include AI & Machine Learning, Cloud, Cyber/Security, Blockchain, IoT, Agile, Data, and Technology Modernization.
"Digital transformation continues to be top of mind for CEOs and business leaders, and demand will only increase as technology rapidly evolves," said
"I chose to focus my career on talent and recruitment because of the lasting impact – both for people and organizations. Taking the time to deeply understand the needs and values of the executives and organizations we serve is the best way to ensure alignment and longevity," said Harms. "At Beecher Reagan, we measure ourselves by long-term retention rates of the leaders we place, as well as the value they add for the firms we serve."
About Beecher Reagan
Beecher Reagan, LLC is the premier retained search firm for transformational leadership in Digital & Technology, Professional Services and Private Equity. The firm connects game-changing executive leaders with firms seeking rapid growth and sustained results. We combine a formidable network of leaders with decades of quantitative behavioral data to connect the right talent with the right purpose in the right culture – maximizing the potential of the leaders and firms we serve. Connect with us at www.beecherreagan.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/beecher-reagan-welcomes-jeff-harms-as-managing-director-301987764.html
SOURCE Beecher Reagan
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Axon Announces Body 5: Next-Generation Camera Built for the AI Era
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share